STIM
$1.24-0.12 (-8.82%)
Neuronetics, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment...
Recent News
Neuronetics, Inc. Q4 2025 Earnings Call Summary
Moby summary of Neuronetics, Inc.'s Q4 2025 earnings call
Neuronetics (STIM) Q4 2025 Earnings Transcript
Before we begin, I would like to caution listeners that certain information discussed by management during this conference call will include forward-looking statements covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements related to our business, strategy, financial and revenue guidance, the Greenbrook integration, and other operational issues and metrics. Actual results can differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business.
Neuronetics Q4 Earnings Call Highlights
Neuronetics (NASDAQ:STIM) reported fourth-quarter 2025 financial and operating results highlighted by its first full year operating with the Greenbrook clinic network, strong adjusted pro forma revenue growth, and positive operating cash flow in the quarter. Management also announced a leadership tr
Neuronetics: Q4 Earnings Snapshot
STIM) on Tuesday reported a loss of $7.2 million in its fourth quarter. On a per-share basis, the Malvern, Pennsylvania-based company said it had a loss of 10 cents. The medical device company focused on psychiatric disorders posted revenue of $41.8 million in the period.
Assessing Neuronetics (STIM) Valuation After Positive Cash Flow And Strong Preliminary Q4 Revenue
Why Neuronetics is back on investor radars Neuronetics (STIM) is drawing fresh attention after reporting preliminary fourth quarter 2025 revenue of US$41.8 million and generating positive operating cash flow of US$0.9 million, supported by NeuroStar system shipments and clinic growth. See our latest analysis for Neuronetics. The preliminary Q4 update has arrived after a year of sharp swings, with a 1 day share price return of 12.22% decline and a 1 year total shareholder return of 59.49%...